Skip to content
Inciteful Med

Standard of Care Treatment

Last updated:

Standard AML treatment involves two main phases: induction therapy to clear leukemia from the bone marrow, followed by consolidation therapy to prevent it from returning. Treatment intensity is customized based on your overall fitness and the specific genetic profile of your leukemia.

Key Takeaways

  • • AML treatment is divided into an induction phase to achieve remission and a consolidation phase to keep the cancer from returning.
  • • Doctors determine your treatment intensity based on a fitness evaluation using ECOG and HCT-CI scores rather than age alone.
  • • Fit patients typically receive intensive 7+3 chemotherapy, while older or less fit patients often receive lower-intensity venetoclax combinations.
  • • Consolidation therapy to prevent relapse may involve high-dose chemotherapy or a donor stem cell transplant.
  • • Targeted therapies like FLT3 or IDH inhibitors may be added to your treatment plan based on the specific genetic mutations in your leukemia.

Once your medical team has identified your specific type of AML, they must move quickly to create a treatment plan. AML treatment is generally divided into two main stages: Induction, which is designed to clear the leukemia from your blood and marrow to achieve a complete remission, and Consolidation, which aims to kill any hidden leukemia cells to keep the cancer from returning [1][2].

Determining Your “Fitness” for Treatment

Because AML treatments can be very taxing on the body, doctors do not simply look at your age. Instead, they evaluate your “fitness” using specific tools [3][4]:

  • ECOG Performance Status: A scale from 0 to 4 that measures your ability to perform daily tasks. A score of 0 means you are fully active, while a higher score indicates more limitation [5].
  • HCT-CI (Comorbidity Index): A point system that tracks other health conditions you may have, such as heart or lung issues. A higher score (typically 3 or more) may mean your body is less able to handle intensive chemotherapy [6][7].

Phase 1: Induction (Achieving Remission)

The goal of this phase is to reduce the number of leukemic blasts in your marrow to less than 5% [2]. There are two primary paths:

1. Intensive Induction (The “7+3” Regimen)

This has been the standard for decades for fit, younger patients. It involves 7 days of a continuous infusion of a drug called Cytarabine, combined with 3 days of an Anthracycline (like Daunorubicin or Idarubicin) [8][9].

  • What to Expect: This usually requires a 3-to-4-week hospital stay [10].
    • Days 1-7: You receive continuous chemotherapy to wipe out the marrow.
    • Day 14 (approx.): A follow-up bone marrow biopsy is often done to check if the leukemia has been cleared (an “empty” marrow).
    • Days 15-28: You wait in the hospital, requiring frequent blood and platelet transfusions, until your healthy blood counts recover [11].
  • Targeted Add-ons: If you have a FLT3 mutation, your doctor may add a targeted drug like Midostaurin or the newly approved Quizartinib to this chemotherapy [12][13].

2. Low-Intensity Induction (Venetoclax + HMA)

For patients who are older or have other health issues, a newer approach is often used. This combines Venetoclax (a pill that helps cancer cells die) with a hypomethylating agent (HMA) like Azacitidine or Decitabine [14][15].

  • What to Expect: While this is “lower intensity” because it is gentler on organs like your heart, it still profoundly suppresses your bone marrow [16]. You will still require intense monitoring, frequent clinic visits, and regular blood and platelet transfusions [17]. To prevent a side effect called Tumor Lysis Syndrome (TLS), the dose of Venetoclax is slowly “ramped up” over the first few days [18].

Phase 2: Consolidation (Staying in Remission)

Once you are in remission, you still need “insurance” therapy to prevent a relapse [1]. Your path depends on your ELN risk group:

  • HiDAC (High-Dose Cytarabine): This involves several short, intense rounds of chemotherapy. It is the preferred path for patients with Favorable-risk AML [19][20].
  • Allo-HSCT (Allogeneic Stem Cell Transplant): This involves replacing your bone marrow with healthy cells from a donor [21]. It is considered the strongest way to prevent a relapse and is typically the standard of care for Intermediate and Adverse-risk patients [22][23].

Targeted and Second-Line (Salvage) Therapies

If AML returns (relapses) or does not respond to the first treatment (refractory), specialized “second-line” or “salvage” (the medical term for backup) therapies may be used:

  • FLT3 Inhibitors: Drugs like Gilteritinib are used specifically for patients with FLT3 mutations that have returned [24][25].
  • IDH Inhibitors: Drugs like Ivosidenib (for IDH1) or Enasidenib (for IDH2) target the specific metabolic “glitch” caused by these mutations [26][27].

By matching the intensity of the treatment to your body’s fitness and the specific “fingerprint” of your leukemia, your team aims to achieve the best possible long-term outcome [12][28].

Frequently Asked Questions

What is the difference between induction and consolidation therapy for AML?
Induction is the first phase of treatment aimed at clearing leukemia cells from your bone marrow to achieve a complete remission. Consolidation is the follow-up therapy designed to eliminate any remaining hidden cancer cells and prevent a relapse.
What is the 7+3 chemotherapy regimen?
The 7+3 regimen is an intensive induction treatment that involves a continuous 7-day infusion of cytarabine paired with 3 days of an anthracycline drug. It typically requires a three to four-week hospital stay while your healthy blood counts recover.
How do doctors decide if I need intensive or low-intensity AML treatment?
Your medical team evaluates your overall fitness using scoring systems like the ECOG performance status and HCT-CI. These tools measure your ability to perform daily tasks and track other health conditions to ensure your body can safely handle the intensity of the treatment.
Can I get targeted therapy for acute myeloid leukemia?
Yes, if your leukemia has specific genetic mutations, doctors can add targeted drugs to your standard treatment. For example, targeted inhibitors may be used specifically to fight leukemia cells with FLT3, IDH1, or IDH2 mutations.
Will I need a stem cell transplant for AML?
An allogeneic stem cell transplant is often recommended during the consolidation phase for patients with intermediate or adverse-risk leukemia. It replaces your bone marrow with healthy donor cells and is considered the strongest way to prevent a relapse.

Questions for Your Doctor

  • • What is my ECOG performance status and HCT-CI score, and how do they impact my treatment choice?
  • • Am I starting the '7+3' intensive regimen or the 'Venetoclax plus HMA' low-intensity regimen?
  • • Will any targeted therapies, such as FLT3 or IDH inhibitors, be added to my treatment based on my genetic profile?
  • • What is the plan for monitoring my response—will I have a bone marrow biopsy around Day 14 or Day 28?
  • • Based on my risk group, is an allogeneic stem cell transplant (allo-HSCT) the ultimate goal after I achieve remission?

Questions for You

  • • How do I feel about the possibility of a 3-4 week hospital stay for intensive induction?
  • • Do I have a support system in place to help me with daily tasks and transportation to frequent clinic visits if I receive low-intensity treatment?
  • • What are my biggest concerns regarding treatment side effects, such as hair loss, nausea, or infection risk?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Maintenance therapy in AML: The past, the present and the future.

    Molica M, Breccia M, Foa R, et al.

    American journal of hematology 2019; (94(11)):1254-1265 doi:10.1002/ajh.25620.

    PMID: 31429099
  2. 2

    Intensified Induction and Post-Remission Therapy for Acute Myeloid Leukaemia.

    Bishop JF

    Hematology (Amsterdam, Netherlands) 1996; (1(2)):91-102 doi:10.1080/10245332.1996.11746292.

    PMID: 27406423
  3. 3

    Alternatives to intensive treatment in patients with AML.

    Himmelstein G, Mascarenhas J, Marcellino BK

    Clinical advances in hematology & oncology : H&O 2021; (19(8)):526-535.

    PMID: 34411072
  4. 4

    Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis.

    Kuron D, Pohlmann A, Angenendt L, et al.

    Annals of hematology 2023; (102(4)):755-760 doi:10.1007/s00277-023-05111-x.

    PMID: 36749402
  5. 5

    Incorporation of a Comorbidity Index in Treatment Decisions for Elderly AML Patients Can Lead to Better Disease Management-A Single-Center Experience.

    Negotei C, Mitu I, Angelescu S, et al.

    Hematology reports 2024; (16(4)):781-794 doi:10.3390/hematolrep16040074.

    PMID: 39728004
  6. 6

    Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review.

    Hao Q, Foroutan F, Han MA, et al.

    PloS one 2022; (17(12)):e0278578 doi:10.1371/journal.pone.0278578.

    PMID: 36469519
  7. 7

    Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan.

    Isobe M, Konuma T, Masuko M, et al.

    Annals of hematology 2021; (100(7)):1849-1861 doi:10.1007/s00277-021-04464-5.

    PMID: 33624134
  8. 8

    Clinical Profile and Short Term Outcome of Adult Patients with Acute Myeloid Leukemia.

    Jacob S, Jacob SE, Suryanarayana BS, Dutta TK

    Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2019; (35(3)):431-436 doi:10.1007/s12288-018-1051-9.

    PMID: 31388253
  9. 9

    Association of leukocyte nadir with complete remission in Indonesian acute myeloid leukemia patients undergoing 7+3 remission induction chemotherapy.

    Hadisantoso DW, Ranuhardy D, Rajabto W, et al.

    F1000Research 2022; (11()):495 doi:10.12688/f1000research.110320.2.

    PMID: 35721596
  10. 10

    Economic burden in US patients with newly diagnosed acute myeloid leukemia receiving intensive induction chemotherapy.

    Huggar D, Knoth RL, Copher R, et al.

    Future oncology (London, England) 2022; (18(32)):3609-3621 doi:10.2217/fon-2022-0706.

    PMID: 36305495
  11. 11

    The Impact of Early Versus Late Platelet and Neutrophil Recovery after Induction Chemotherapy on Survival Outcomes of Patients with Acute Myeloid Leukemia

    Çiftçiler R, Haznedaroğlu İC, Sayınalp N, et al.

    Turkish journal of haematology : official journal of Turkish Society of Haematology 2020; (37(2)):116-120 doi:10.4274/tjh.galenos.2019.2019.0154.

    PMID: 31475513
  12. 12

    Contemporary Management of Acute Myeloid Leukemia: A Review.

    Venugopal S, Sekeres MA

    JAMA oncology 2024; (10(10)):1417-1425 doi:10.1001/jamaoncol.2024.2662.

    PMID: 39115831
  13. 13

    Acute myeloid leukemia management and research in 2025.

    Kantarjian HM, DiNardo CD, Kadia TM, et al.

    CA: a cancer journal for clinicians 2025; (75(1)):46-67 doi:10.3322/caac.21873.

    PMID: 39656142
  14. 14

    SOHO State of the Art Updates and Next Questions: The Past, Present and Future of Venetoclax-Based Therapies in AML.

    Inguva A, Pollyea DA

    Clinical lymphoma, myeloma & leukemia 2021; (21(12)):805-811 doi:10.1016/j.clml.2021.07.012.

    PMID: 34389272
  15. 15

    Venetoclax in acute myeloid leukemia - current and future directions.

    Lachowiez C, DiNardo CD, Konopleva M

    Leukemia & lymphoma 2020; (61(6)):1313-1322 doi:10.1080/10428194.2020.1719098.

    PMID: 32031033
  16. 16

    Feasibility, safety and outcomes of patients with newly diagnosed acute myeloid leukemia discharged 'early' after intensive induction.

    Hunter CJ, Cheng W, Bewersdorf JP, et al.

    Leukemia & lymphoma 2026; (67(1)):164-175 doi:10.1080/10428194.2025.2578420.

    PMID: 41160735
  17. 17

    Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.

    Pollyea DA, Pratz K, Letai A, et al.

    American journal of hematology 2021; (96(2)):208-217 doi:10.1002/ajh.26039.

    PMID: 33119898
  18. 18

    Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy.

    Richard-Carpentier G, DiNardo CD

    Therapeutic advances in hematology 2019; (10()):2040620719882822 doi:10.1177/2040620719882822.

    PMID: 31692757
  19. 19

    Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?

    Derman BA, Larson RA

    Best practice & research. Clinical haematology 2019; (32(4)):101102 doi:10.1016/j.beha.2019.101102.

    PMID: 31779969
  20. 20

    Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT.

    Al Hamed R, Labopin M, Wu D, et al.

    Bone marrow transplantation 2024; (59(10)):1458-1465 doi:10.1038/s41409-024-02373-5.

    PMID: 39095548
  21. 21

    What's new in consolidation therapy in AML?

    Schlenk RF, Jaramillo S, Müller-Tidow C

    Seminars in hematology 2019; (56(2)):96-101 doi:10.1053/j.seminhematol.2018.08.005.

    PMID: 30926097
  22. 22

    New approaches in allogenic transplantation in AML.

    Pei X, Huang X

    Seminars in hematology 2019; (56(2)):147-154 doi:10.1053/j.seminhematol.2018.08.007.

    PMID: 30926091
  23. 23

    Is There Still a Role for Autologous Stem Cell Transplantation for the Treatment of Acute Myeloid Leukemia?

    Ferrara F, Picardi A

    Cancers 2019; (12(1)) doi:10.3390/cancers12010059.

    PMID: 31878297
  24. 24

    Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation.

    Ballesta-López O, Solana-Altabella A, Megías-Vericat JE, et al.

    Future oncology (London, England) 2021; (17(2)):215-227 doi:10.2217/fon-2020-0700.

    PMID: 32975130
  25. 25

    Treatment for Relapsed/Refractory Acute Myeloid Leukemia.

    Thol F, Heuser M

    HemaSphere 2021; (5(6)):e572 doi:10.1097/HS9.0000000000000572.

    PMID: 34095756
  26. 26

    FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.

    Norsworthy KJ, Luo L, Hsu V, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2019; (25(11)):3205-3209 doi:10.1158/1078-0432.CCR-18-3749.

    PMID: 30692099
  27. 27

    Isocitrate dehydrogenase inhibitors in acute myeloid leukemia.

    Liu X, Gong Y

    Biomarker research 2019; (7()):22 doi:10.1186/s40364-019-0173-z.

    PMID: 31660152
  28. 28

    [Novel Strategies to Treat Acute Myeloid Leukemia].

    Gediga MHE, Middeke JM, Ruhnke L

    Deutsche medizinische Wochenschrift (1946) 2023; (148(8)):451-458 doi:10.1055/a-1873-4753.

    PMID: 36990117

This page explains standard acute myeloid leukemia (AML) treatments for educational purposes. Always consult your oncologist to determine the best treatment plan for your specific fitness level and genetic profile.

Stay up to date

Get notified when new research about Acute myeloid leukemia is published.

No spam. Unsubscribe anytime.